For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

VEGF: a marker of angiogenesis with potential as a prognostic cancer biomarker

Related

  • VEGF product portfolio
    • VEGF antibodies
      • VEGF ELISA Kits
        • VEGF-A product portfolio
          • VEGF Receptor Inhibitors
            • Angiogenesis antibody arrays
              • Angiogenesis assay kit
                  • VEGF resources
                    • VEGF interactive pathway
                        • Recombinant RabMAb® antibodies
                          • Recombinant antibodies
                              • Secondary antibodies

                                Vascular endothelial growth factor (VEGF) is a key contributor in the formation of new blood vessels.

                                ​​

                                VEGF can induce growth of pre-existing (angiogenesis) or de novo vessels (vasculogenesis), and is therefore key for embryonic development and vessel repair. VEGF is also hijacked by solid tumors to support their neoplastic growth.

                                The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor 1 and 2 (PIGF-1 and PIGF-2, respectively)1,2. VEGF-A is the most potent inducer of blood vessel growth known to date, whereas VEGF-E is more specific for localized pathological processes of angiogenesis.

                                Family members are encoded by multiple exons that can give rise different isoforms after alternative splicing, with consequences on solubility and receptor binding3. For example, VEGF-A exists in seven isoforms, while VEGF-B presents two isoforms.

                                VEGF family members transduce their signal intercellularly by binding to membrane-bound tyrosine kinase receptors: VEGF-A and B have a preference for VEGFR-1; VEGF-A, C, D and E can bind to VEGFR-2; VEGF-C and D to VEGFR-3 (expressed only in hematopoietic cells). The activation of VEGF receptors is considered one of the most critical events in angiogenesis3.

                                Explore our VEGF product portfolio

                                Contents

                                • VEGF signaling pathways
                                • VEGF and the formation of new blood vessels
                                • VEGF's value as a prognostic cancer biomarker 
                                • Antibodies, recombinant proteins, and assay kits to study VEGF receptors and their ligands
                                • Antibodies, inhibitors, and assay kits VEGF downstream signaling
                                • Human angiogenesis antibody arrays



                                VEGF signaling pathways

                                VEGF has activity in diverse cell types, such as muscle4 and neuronal cells5, however its main actions are on endothelial cells6. Family members play key roles in orchestrating the formation of new blood vessels, such as induction of gene expression, regulation of vascular permeability, and promotion of cell migration, proliferation and survival.

                                These are all induced by the binding of VEGF to VEGF-Rs, and the resulting activation of multiple downstream signaling pathways. These include: the Ras/MAPK pathway to regulate cell proliferation and gene expression; the FAK/paxillin pathway involved in the rearrangement of the cytoskeleton; the PI3K/AKT pathway regulating cell survival; the RhoA/ROCK pathway to form of new capillaries; the PLCγ pathway which controls vascular permeability6,7.


                                VEGF and the formation of new blood vessels

                                High levels of VEGF are observed during embryo development, where it cooperates with multiple endothelial growth factors to control the formation of new blood vessels1. As a consequence, disruption of VEGF pathways in mice increases embryonic lethality due to circulatory problems8.

                                Expression of VEGF decreases significantly after birth. However, localized levels can be up-regulated in tissues undergoing wound healing or fracture repair2. Recent studies have emphasized the role VEGF plays in pathological conditions involving the formation of new blood vessels, such as cancer, rheumatoid arthritis and age-related macular degeneration3,9,10.

                                Once the angiogenic switch is induced to promote the formation of new blood vessels, a complex and highly regulated sequence of events takes place. By activating multiple proteases, this pathway promotes the degradation of the basement membrane surrounding the existing vessel. This is followed by increased proliferation of endothelial cells, the formation of a lumen and a new basement membrane, and the fusion of newly formed vessels2.


                                VEGF's value as a prognostic cancer biomarker

                                Immunohistochemistry analysis of VEGF and its family members has been associated with the prognosis of multiple cancer types including; cervical cancer11, oral cancer12, multiple lung cancers13, colorectal cancers14, ovarian cancer15, renal cancer16 and liver cancer17​.

                                ​​

                                Get your project underway with antibodies, recombinant proteins, and assay kits to study VEGF receptors and their ligands.



                                VEGFA

                                VEGF Receptor 1

                                VEGF Receptor 2

                                Antibody

                                Rabbit monoclonal (ab1316)

                                Rabbit monoclonal (ab32152)

                                Rabbit polyclonal (ab39256)

                                Inhibitor

                                Melittin (ab143517)

                                ZM306416 hydrochloride (ab144576)

                                AZD4547 (ab216311)

                                Recombinant protein

                                VEGFA protein (ab9571)

                                VEGF R1 protein (ab84771)

                                VEGF R2 protein (ab106310)

                                Human ELISA Kit

                                VEGF ELISA Kit (ab100663)

                                VEGF R1 ELISA Kit (FLT1) (ab195210)

                                VEGF R2 ELISA Kit (ab213476)



                                Add antibodies, inhibitors and assay kits to your reagents to study VEGF downstream signaling.



                                RAS/MAPK

                                FAK/Paxillin

                                PI3K/AKT

                                Total and phospho antibodies


                                Rabbit mono to Ras (ab52939)

                                Rabbit mono to FAK (ab40794)

                                Rabbit mono to AKT1 (ab32505)

                                Rabbit mono to ERK1+ERK2 (ab184699)

                                Rabbit mono to Paxillin (ab32084)

                                Mouse mono to PI3K (ab86714)

                                Rabbit mono to ERK1 pT202 +ERK2 pT185 (ab201015)

                                Rabbit mono to Paxillin pY31 (ab32115)

                                Rabbit mono to AKT pS437 (ab81283)

                                Rabbit mono to PI3K pY607 (ab182651)

                                Activity and detection kits

                                Ras GTPase ELISA Kit (ab134640)

                                Human FAK ELISA Kit (ab187395)

                                Akt + Akt pS473 ELISA (ab126433)

                                Mouse FAK Matched Antibody Pair Kit (ab215072)

                                Akt Kinase Activity Assay (ab139436)

                                Pathway inhibition

                                p38 inhibtor SB202190 (ab120638)

                                FAK inhibitor 14 (ab144503)

                                Akt inhibitor Akti-1/2 (ab142088)

                                JNK inhibitor (ab120065)

                                PF-562271 FAK inhibitor (ab141360)

                                TGX-221 PI3K inhibitor (ab120924)



                                Simultaneously detect up to 60 angiogenesis factors in serum, plasma, other body fluids, cell culture media, cell and tissue lysates, with our human angiogenesis antibody arrays


                                Array format (product code)

                                Angiogenesis factors detected

                                WB-like

                                detection

                                Laser scanner

                                detection

                                Membrane (ab193655)

                                43

                                ♦


                                Membrane (ab134000)

                                20

                                ♦


                                Membrane (ab169808)

                                23

                                ♦


                                Slide – Quantitative (ab197419)

                                10


                                ♦

                                Slide A – Quantitative (ab197420)

                                30


                                ♦

                                Slide B – Quantitative (ab197421)

                                30


                                ♦

                                Slide – Quantitative (ab197418)

                                60


                                ♦


                                References

                                • 1. Gilbert, SF (2000) Developmental biology (6th Edition). Sunderland (MA): Sinauer Associates.
                                • 2. Adair, TH and Montani JP (2010) Angiogenesis. San Rafael (CA): Morgan & Claypool Life Sciences; 2010.
                                • 3. Sullivan LA and Brekken RA (2010) The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs. 2010 Mar-Apr; 2(2): 165–175.
                                • 4. Bryan B, Walshe T, Mitchell D, Havumaki J, Saint-Geniez M, Maharaj A, Maldonado A and D'Amore P (2008) Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic Differentiation. Mol Biol Cell. 2008 March; 19(3): 994–1006.
                                • 5. Jin K, Mao XO, Greenberg DA. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol. 2006 Feb 15;66(3):236-42.
                                • 6. Lee S, Chen T, Barber C, Jordan M, Murdock J, Desai S, Ferrara N, Nagy A, Roos K and Iruela-Arispe M (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007 August 24; 130(4): 691–703.
                                • 7. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7.
                                • 8. Ji Y, Lu X, Zhong Q, Liu P, An Y, Zhang Y, Zhang S, Jia R, Tesfamariam IG, Kahsay AG, Zhang L, Zhu W, Zheng Y (2013). Transcriptional profiling of mouse uterus at pre-implantation stage under VEGF repression. PLoS One. 8(2):e57287.
                                • 9. Szekanecz Z, Besenyei T, Paragh G, Koch AE (2009) Angiogenesis in rheumatoid arthritis. Autoimmunity. 42(7):563-73.
                                • 10. Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS (2013) VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013 Apr;182(4):1379-90.
                                • 11. Rahmani A H, Babiker A Y, Alsahli M A, Almatroodi S A and Husain N E O S (2018) Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma. Maced J Med Sci. 2018 Feb 15; 6(2); 263-268
                                • 12. Lee L T, Wong Y K, Chan M Y, Chang K W, Chen S C, Chang C T & Wang J (2018) The correlation between HIF-1 alpha and VEGF in oral squamous cell carcinomas: Expression patterns and quantitative immunohistochemical analysis. Journal of the Chinese Medical Association. 2015 Apr; 81 (4): 370- 375
                                • 13. Usuda K, Iwai S, Funasaki A, Sekimura A, Motono N, Ueda Y, Shimazaki M and Uramoto H (2018) Expression and Prognostic Impact of VEGF, CD31 and αSMA in Resected Primary Lung Cancers. Anticancer research. 2018 July; 38(7): 4057 – 4063
                                • 14. Mohamed S Y, Mohamed H L, Ibrahim H M, Elshaimaa M M and Salah M (2017) Role of VEGF, CD105 and CD31 in the Prognosis of Colorectal Cancer Cases. Journal of Gastrointestinal Reseearch. 2019 March; 50 (1): 23-34
                                • 15. Guo B Q and Lu W Q (2018) The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer. Oncotarget. 2018 July 17; 9(55): 30552-30560
                                • 16. Osman W M and Youssef N S (2015) Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma. Int J Clin Exp Pathol. 2015; 8(7): 8165-8177
                                • 17. Cao G, Li X, Qin C and Li J (2015) Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015 Oct 18; 21: 3144-3151
                                • 18. Peña, A., Lathia, C., Shan, M., Escudier, B., and Bukowski, R. M. (2010) Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clinical Cancer Research; 16(19):4853-63
                                Get resources and offers direct to your inbox Sign up
                                A-Z by research area
                                • Cancer
                                • Cardiovascular
                                • Cell biology
                                • Developmental biology
                                • Epigenetics & Nuclear signaling
                                • Immunology
                                • Metabolism
                                • Microbiology
                                • Neuroscience
                                • Signal transduction
                                • Stem cells
                                A-Z by product type
                                • Primary antibodies
                                • Secondary antibodies
                                • Biochemicals
                                • Isotype controls
                                • Flow cytometry multi-color selector
                                • Kits
                                • Loading controls
                                • Lysates
                                • Peptides
                                • Proteins
                                • Slides
                                • Tags and cell markers
                                • Tools & Reagents
                                Help & support
                                • Support
                                • Make an Inquiry
                                • Protocols & troubleshooting
                                • Placing an order
                                • RabMAb products
                                • Biochemical product FAQs
                                • Training
                                • Browse by Target
                                Company
                                • Corporate site
                                • Investor relations
                                • Company news
                                • Careers
                                • About us
                                • Blog
                                Events
                                • Tradeshows
                                • Conferences
                                International websites
                                • abcam.cn
                                • abcam.co.jp

                                Join with us

                                • LinkedIn
                                • facebook
                                • Twitter
                                • YouTube
                                • Terms of sale
                                • Website terms of use
                                • Cookie policy
                                • Privacy policy
                                • Legal
                                • Modern slavery statement
                                © 1998-2022 Abcam plc. All rights reserved.